We are live on ! Find out more
HRTX icon

Heron Therapeutics
HRTX

161 hedge funds and large institutions have $176M invested in Heron Therapeutics in 2024 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 42 increasing their positions, 51 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

7,109% more call options, than puts

Call options by funds: $4.61M | Put options by funds: $64K

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

4.75% less ownership

Funds ownership: 80.32% → 75.57% (-4.8%)

7% less funds holding

Funds holding: 173 → 161 (-12)

18% less repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 51

26% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 35

27% less capital invested

Capital invested by funds: $242M → $176M (-$66.6M)

Holders
161
Holders Change
-12
Holders Change %
-6.94%
% of All Funds
2.12%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
26
Increased
42
Reduced
51
Closed
35
Calls
$4.61M
Puts
$64K
Net Calls
+$4.55M
Net Calls Change
+$4.47M

Top Buyers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4.99M
2
Morgan Stanley
Morgan Stanley
New York
+$1.66M
3
SCM
Stonepine Capital Management
Oregon
+$1.13M
4
CPC
Congress Park Capital
New York
+$774K
5
QOP
Quinn Opportunity Partners
Virginia
+$616K

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$2.58M
2
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$2.28M
3
Goldman Sachs
Goldman Sachs
New York
-$1.71M
4
Renaissance Technologies
Renaissance Technologies
New York
-$1.33M
5
N
Nuveen
North Carolina
-$1.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
RCMNY
1
Rubric Capital Management (New York)
New York
$40.9M – – –
BlackRock
2
BlackRock
New York
$13.1M +$91K +56,175 +0.7%
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$13M -$567K -350,000 -4%
Vanguard Group
4
Vanguard Group
Pennsylvania
$12.5M -$912K -562,567 -6%
VCIM
5
Velan Capital Investment Management
Georgia
$10.7M – – –
TC
6
Tejara Capital
United Kingdom
$7.13M -$1.04M -644,269 -12%
PCM
7
Palisade Capital Management
New Jersey
$6.01M -$107K -65,889 -2%
D.E. Shaw & Co
8
D.E. Shaw & Co
New York
$5.7M -$1.07M -660,971 -15%
State Street
9
State Street
Massachusetts
$4.81M -$75K -46,243 -1%
Point72 Asset Management
10
Point72 Asset Management
Connecticut
$4.71M +$4.99M +3,075,809 New
Geode Capital Management
11
Geode Capital Management
Massachusetts
$4.61M -$48.7K -30,034 -1%
Morgan Stanley
12
Morgan Stanley
New York
$4.28M +$1.66M +1,025,837 +58%
CPC
13
Congress Park Capital
New York
$3.76M +$774K +477,417 +24%
JAM
14
JW Asset Management
Florida
$3.51M – – –
TCM
15
Tang Capital Management
California
$3.27M +$470K +290,271 +16%
OCM
16
Orchard Capital Management
Illinois
$2.84M -$168K -103,738 -5%
CC
17
Clearline Capital
New York
$2.77M -$674K -416,029 -19%
New York State Common Retirement Fund
18
New York State Common Retirement Fund
New York
$2.02M +$66.6K +41,062 +3%
MAM
19
Monaco Asset Management
Monaco
$1.86M -$755K -465,674 -28%
Renaissance Technologies
20
Renaissance Technologies
New York
$1.82M -$1.33M -819,398 -41%
Charles Schwab
21
Charles Schwab
California
$1.69M +$15.3K +9,418 +0.9%
Bank of America
22
Bank of America
North Carolina
$1.6M +$147K +90,862 +10%
Marshall Wace
23
Marshall Wace
United Kingdom
$1.56M -$1.13M -698,006 -41%
Northern Trust
24
Northern Trust
Illinois
$1.55M +$35.3K +21,769 +2%
Two Sigma Investments
25
Two Sigma Investments
New York
$1.51M -$668K -411,906 -29%
1
2 3 4 5

HRTX Hedge Fund Activity: Q4 2024 in Review

161 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q4 2024, worth a combined $176M — down 27% from $242M a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of HRTX and 26 opened new positions — a net loss of 9 holders — while 51 trimmed existing stakes and 42 added.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $4.99M. The largest seller was Citadel Advisors, exiting entirely with an estimated $2.58M sold.

  • 161 institutional investors held Heron Therapeutics (HRTX) as of Q4 2024, down from 173 in Q3 2024.
  • Funds reported $176M of Heron Therapeutics stock for Q4 2024, down 27% quarter-over-quarter.
  • 26 funds opened new Heron Therapeutics positions in Q4 2024 and 35 closed out, a net change of -9 holders.
  • The largest Heron Therapeutics buyer in Q4 2024 was Point72 Asset Management, an estimated $4.99M added.
  • The largest Heron Therapeutics seller in Q4 2024 was Citadel Advisors, an estimated $2.58M sold.

Based on aggregated 13F filings for Q4 2024.